TY - JOUR
T1 - Cardiac characteristics of Fabry disease from baseline enrolment data in a nationwide prospective Japanese registry
AU - Kubo, Toru
AU - Maekawa, Yuichiro
AU - Hongo, Kenichi
AU - Yamamoto, Saori
AU - Izumiya, Yasuhiro
AU - Yamakawa, Hiroyuki
AU - Yano, Toshiyuki
AU - Higuchi, Koji
AU - Kuramoto, Yuki
AU - Nakagawa, Naoki
AU - Amano, Masashi
AU - Yamada, Yu
AU - Oikawa, Masayoshi
AU - Iida, Yuichiro
AU - Tsujita, Kenichi
AU - Matsue, Yuya
AU - Izawa, Hideo
AU - Suzuki, Atsushi
AU - Nagatomo, Yuji
AU - Nagai, Toshiyuki
AU - Kida, Keisuke
AU - Nakamura, Kazuto
AU - Nakamura, Kazufumi
AU - Ikenaga, Hiroki
AU - Kanda, Takahiro
AU - Kinugasa, Yoshiharu
AU - Ito, Hiromasa
AU - Onoue, Kenji
AU - Kanamori, Hiromitsu
AU - Kitaoka, Hiroaki
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2026/2/15
Y1 - 2026/2/15
N2 - Background: Fabry disease (FD) is an important disease in the cardiovascular field because a significant proportion of patients with FD die from cardiac lesions. Methods: A multicenter prospective registration study of patients with FD throughout Japan was designed. The baseline clinical characteristics of 175 patients are presented here. Results: The mean ages at enrolment and at diagnosis were 52 ± 16 and 43 ± 18 years, respectively, with men accounting for 38 % of the patients. In the cohort, 24 % of the patients had the classical hemizygote male type, whereas 14 % had the late-onset male type, and 62 % had the heterozygote female type. On electrocardiography data at enrolment in 92 patients with left ventricular hypertrophy (LVH) (maximum LV wall thickness > 12 mm), 12 % showed a short PQ interval (< 120 msec), and 33 % had a short PendQ interval (≤ 40 msec). The Sokolow-Lyon voltage was high (6.1 ± 13.1 mv). Regarding the distribution of LVH patterns, 77 % of the patients showed concentric diffuse LVH, 16 % of the patients had asymmetric septal hypertrophy, and 1 % of the patients had hypertrophy confined to the LV apex. With regard to implantation of cardiac devices, permanent pacemakers had been implanted in 5 % of the patients and defibrillators had been implanted in 12 patients (7 %), for primary prevention in nine patients and for secondary prevention in three patients. Conclusion: As the first large-scale prospective registry of FD patients in Japan, this study has provided valuable baseline data for the cardiac features and management of FD.
AB - Background: Fabry disease (FD) is an important disease in the cardiovascular field because a significant proportion of patients with FD die from cardiac lesions. Methods: A multicenter prospective registration study of patients with FD throughout Japan was designed. The baseline clinical characteristics of 175 patients are presented here. Results: The mean ages at enrolment and at diagnosis were 52 ± 16 and 43 ± 18 years, respectively, with men accounting for 38 % of the patients. In the cohort, 24 % of the patients had the classical hemizygote male type, whereas 14 % had the late-onset male type, and 62 % had the heterozygote female type. On electrocardiography data at enrolment in 92 patients with left ventricular hypertrophy (LVH) (maximum LV wall thickness > 12 mm), 12 % showed a short PQ interval (< 120 msec), and 33 % had a short PendQ interval (≤ 40 msec). The Sokolow-Lyon voltage was high (6.1 ± 13.1 mv). Regarding the distribution of LVH patterns, 77 % of the patients showed concentric diffuse LVH, 16 % of the patients had asymmetric septal hypertrophy, and 1 % of the patients had hypertrophy confined to the LV apex. With regard to implantation of cardiac devices, permanent pacemakers had been implanted in 5 % of the patients and defibrillators had been implanted in 12 patients (7 %), for primary prevention in nine patients and for secondary prevention in three patients. Conclusion: As the first large-scale prospective registry of FD patients in Japan, this study has provided valuable baseline data for the cardiac features and management of FD.
KW - Fabry disease
KW - Left ventricular hypertrophy
KW - Prospective study
KW - Treatment
UR - https://www.scopus.com/pages/publications/105024321784
UR - https://www.scopus.com/pages/publications/105024321784#tab=citedBy
U2 - 10.1016/j.ijcard.2025.134071
DO - 10.1016/j.ijcard.2025.134071
M3 - Article
C2 - 41352439
AN - SCOPUS:105024321784
SN - 0167-5273
VL - 445
JO - International Journal of Cardiology
JF - International Journal of Cardiology
M1 - 134071
ER -